Olanzapine for chemotherapy-induced nausea and vomiting: A systematic review

Supportive Care in Cancer

Volumn 22, Issue 4, 2014, Pages 1143-1151

  Hocking, Christopher M ^a   Kichenadasse, Ganessan ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

Chemotherapy induced nausea and vomiting; Clinical trials; Olanzapine; Supportive care

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; AZASETRON; CARBOPLATIN; CISPLATIN; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; OLANZAPINE; OXALIPLATIN; PALONOSETRON;

CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG EFFICACY; HUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN; SYSTEMATIC REVIEW; TOXICITY TESTING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; HUMANS; NAUSEA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VOMITING;

EID: 84895880076     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2138-y     Document Type: Review

References (29)

1. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497-503. doi: 10.1007/s00520-006-0173-z
2. Billio A, Morello E, ClarkeMJ (2010) Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst Rev 1, CD006272. doi: 10.1002/14651858.CD006272.pub2
3. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocol 052 Study G (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22):4112-4119. doi: 10.1200/JCO.2003.01.095 (Pubitemid 46606178)
4. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M,Warr D, Group EMGW(2010) Guideline update forMASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232-v243. doi: 10.1093/annonc/mdq194
5. Navari RM (2013) Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs 73(3):249-262. doi: 10.1007/s40265-013-0019-1
6. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study G (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090-3098. doi: 10.1002/cncr.11433 (Pubitemid 36676265)
7. Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, von Pawel J, Giezek H, Ahmed T, Chan CY(2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17(6):1000 -1006. doi: 10.1093/annonc/mdl019
8. SaitoM, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115-124. doi: 10.1016/S1470-2045(08)70313-9
9. Aapro M, Rossi G, Rizzi G, Palmas M, Grunberg S (2013) Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetic chemotherapy (MEC). 2013 ASCO Annual Meeting Abstract LBA9514. Presented June 1st 2013
10. National Comprehensive Cancer Network (2013) Antiemesis Version 1.2013. www.nccn.org . Accessed 30 Apr 2013
11. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P,Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14(2):87-96. doi: 10.1016/0893-133X(94) 00129-N
12. Food and Drug Administration (2011) Zyprexa prescribing information. www.fda.gov . Accessed 30 Apr 2013
13. Rudd JA, Ngan MP, Wai MK, King AG, Witherington J, Andrews PL, Sanger GJ (2006) Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett 392(1-2):79-83. doi: 10.1016/j.neulet.2005.08.062 (Pubitemid 41757580)
14. Kaneishi K, Kawabata M, Morita T (2012) Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manag 44(4):604-607. doi: 10.1016/j.jpainsymman.2011.10.023
15. Shinjo T, Okada M (2006) Olanzapine use in cancer patients for refractory vomiting. Gan To Kagaku Ryoho 33(3):349-352
16. SrivastavaM, Brito-DellanN,DavisMP, Leach M, Lagman R (2003) Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manag 25(6):578-582 (Pubitemid 36629280)
17. Navari RM, Einhorn LH, Loehrer PJ Sr, Passik SD, Vinson J, McClean J, Chowhan N, Hanna NH, Johnson CS (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 15(11):1285-1291. doi: 10.1007/s00520-007-0248-5 (Pubitemid 47583449)
18. Navari RM, Einhorn LH, Passik SD, Loehrer PJ Sr, Johnson C, Mayer ML, McClean J, Vinson J, Pletcher W (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 13(7):529-534. doi: 10.1007/s00520-004-0755-6 (Pubitemid 40933610)
19. Passik SD, Navari RM, Jung SH, Nagy C, Vinson J, Kirsh KL, Loehrer P (2004) A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Investig 22(3):383-388 (Pubitemid 39310908)
20. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1-12 (Pubitemid 26120810)
21. Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9(5):188-195. doi: 10.1016/j.suponc.2011.05.002
22. Shumway NM, Terrazzino SE, Jones CB (2009) A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy-induced nausea and vomiting. Journal of Clinical Oncology: Annual ASCO meeting 27(15)
23. Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, Zhang D (2009) Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:131. doi: 10.1186/1756-9966-28-131
24. Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapyinduced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21(6):1655-1663. doi: 10.1007/s00520-012-1710-6
25. Navari RM, Gray S (2010) Treatment of chemotherapy-induced breakthrough nausea and vomiting. Conference publication: 7th annual conference of the American Psychosocial Oncology Society
26. Navari RM, Gray SE (2009) Treatment of chemotherapy-induced breakthrough nausea and vomiting. Conference publication: 2009 annual meeting of the American Society of Clinical Oncology
27. National Comprehensive Cancer Network (2013) Antiemesis Version 1.2014. www.nccn.org . Accessed 12 Dec 2013
28. Australian Pharmaceutical Benefits Scheme (2013) Schedule of pharmaceutical benefits. www.pbs.gov.au . Accessed 12 Dec 2013
29. Ishiguro H, Kawaguchi K, Nishimura T, Toi M (2013) Antipsychotics- containing regimen as an alternative to standard antiemetics for delayed nausea induced by highly emetogenic chemotherapy. J Clin Oncol 31(10):1377-1378. doi: 10.1200/JCO.2012.47.2951